Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation of stock price appreciation exceeding 15% over the next six months [3][11]. Core Insights - The company achieved a revenue of 6.7 billion yuan in 2025, reflecting an adjusted year-on-year growth of 8.83%. The net profit attributable to shareholders was 1.739 billion yuan, with an adjusted year-on-year increase of 11.66% [1]. - The revenue from the pharmaceutical industry continues to optimize, with its share of total revenue rising to 98.26%, a 4.38 percentage point increase. The growth rate for this segment reached 13.91% [1]. - The company has increased its R&D investment, with the ratio of R&D expenditure to revenue rising by 1.62 percentage points to 5.03%. Significant scientific achievements include the identification of a new active peptide from the main component of donkey-hide gelatin [2]. - The company is actively expanding its business through acquisitions, including the purchase of 80% of Inner Mongolia Alashan Cistanche Group and 70% of Dongfeng Maji Pharmaceutical, to enhance its product ecosystem [2]. Financial Summary - In 2025, the company reported a net operating cash flow of 2.289 billion yuan, with a year-on-year growth of 5.45% [1]. - The projected revenues for 2026, 2027, and 2028 are 7.637 billion yuan, 8.644 billion yuan, and 9.688 billion yuan, respectively, with net profits expected to be 2.049 billion yuan, 2.387 billion yuan, and 2.695 billion yuan [3][4]. - The earnings per share are forecasted to be 3.18 yuan, 3.71 yuan, and 4.18 yuan for the years 2026, 2027, and 2028, respectively [3][4].